-
1
-
-
78049485263
-
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
-
Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127(12):2893-917
-
(2010)
Int J Cancer
, vol.127
, Issue.12
, pp. 2893-2917
-
-
Ferlay, J.1
Shin, H.R.2
Bray, F.3
-
2
-
-
1842531487
-
Cancer care ontario practice guidelines initiative lung cancer disease site G. Photodynamic therapy in nonsmall cell lung cancer: A systematic review
-
Maziak DE, Markman BR, MacKay JA, et al. Cancer care ontario practice guidelines initiative lung cancer disease site G. Photodynamic therapy in nonsmall cell lung cancer: a systematic review. Ann Thorac Surg 2004;77(4):1484-91
-
(2004)
Ann Thorac Surg
, vol.77
, Issue.4
, pp. 1484-1491
-
-
Maziak, D.E.1
Markman, B.R.2
Mackay, J.A.3
-
4
-
-
77449141842
-
Role of cell cycle regulators in lung carcinogenesis
-
National Cancer Institute: SEER Cancer Statistics Review 1973-2008. US National Institutes of Health
-
National Cancer Institute: SEER Cancer Statistics Review, 1973-2008. US National Institutes of Health, Eymin B, Gazzeri S. Role of cell cycle regulators in lung carcinogenesis. Cell Adh Migr 2010;4(1):114-23
-
(2010)
Cell Adh Migr
, vol.4
, Issue.1
, pp. 114-123
-
-
Eymin, B.1
Gazzeri, S.2
-
5
-
-
0034910622
-
Molecular genetics of small cell lung carcinoma
-
Wistuba II, Gazdar AF, Minna JD. Molecular genetics of small cell lung carcinoma. Semin Oncol 2001;28(Suppl 4):3-13
-
(2001)
Semin Oncol
, vol.28
, Issue.SUPPL. 4
, pp. 3-13
-
-
Wistuba, I.I.1
Gazdar, A.F.2
Minna, J.D.3
-
6
-
-
0028124690
-
Aberrant RB gene expression in routinely processed, archival tumor tissues determined by three different anti-RB antibodies
-
Geradts J, Hu SX, Lincoln CE, et al. Aberrant RB gene expression in routinely processed, archival tumor tissues determined by three different anti-RB antibodies. Int J Cancer 1994;58(2):161-7
-
(1994)
Int J Cancer
, vol.58
, Issue.2
, pp. 161-167
-
-
Geradts, J.1
Hu, S.X.2
Lincoln, C.E.3
-
7
-
-
17144465526
-
Cyclin D1 and retinoblastoma susceptibility gene alterations in non-small cell lung cancer
-
Marchetti A, Doglioni C, Barbareschi M, et al. Cyclin D1 and retinoblastoma susceptibility gene alterations in non-small cell lung cancer. Int J Cancer 1998;75(2):187-92
-
(1998)
Int J Cancer
, vol.75
, Issue.2
, pp. 187-192
-
-
Marchetti, A.1
Doglioni, C.2
Barbareschi, M.3
-
8
-
-
0030043970
-
Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer
-
Betticher DC, Heighway J, Hasleton PS, et al. Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer. Br J Cancer 1996;73(3):294-300
-
(1996)
Br J Cancer
, vol.73
, Issue.3
, pp. 294-300
-
-
Betticher, D.C.1
Heighway, J.2
Hasleton, P.S.3
-
9
-
-
33845951110
-
Cyclin D1 in non-small cell lung cancer: A key driver of malignant transformation
-
Gautschi O, Ratschiller D, Gugger M, et al. Cyclin D1 in non-small cell lung cancer: a key driver of malignant transformation. Lung Cancer 2007;55(1):1-14
-
(2007)
Lung Cancer
, vol.55
, Issue.1
, pp. 1-14
-
-
Gautschi, O.1
Ratschiller, D.2
Gugger, M.3
-
10
-
-
0034780882
-
Cyclin D1, p16 and retinoblastoma gene product expression as a predictor for prognosis in non-small cell lung cancer at stages i and II
-
Jin M, Inoue S, Umemura T, et al. Cyclin D1, p16 and retinoblastoma gene product expression as a predictor for prognosis in non-small cell lung cancer at stages I and II. Lung Cancer 2001;34(2):207-18
-
(2001)
Lung Cancer
, vol.34
, Issue.2
, pp. 207-218
-
-
Jin, M.1
Inoue, S.2
Umemura, T.3
-
11
-
-
0035863322
-
Cyclin e is the only cyclin-dependent kinase 2-associated cyclin that predicts metastasis and survival in early stage non-small cell lung cancer
-
Muller-Tidow C, Metzger R, Kugler K, et al. Cyclin E is the only cyclin-dependent kinase 2-associated cyclin that predicts metastasis and survival in early stage non-small cell lung cancer. Cancer Res 2001;61(2):647-53
-
(2001)
Cancer Res
, vol.61
, Issue.2
, pp. 647-653
-
-
Muller-Tidow, C.1
Metzger, R.2
Kugler, K.3
-
12
-
-
0035866753
-
A risk-stratification model of non-small cell lung cancers using cyclin E, Ki-67, and ras p21: Different roles of G1 cyclins in cell proliferation and prognosis
-
Dosaka-Akita H, Hommura F, Mishina T, et al. A risk-stratification model of non-small cell lung cancers using cyclin E, Ki-67, and ras p21: different roles of G1 cyclins in cell proliferation and prognosis. Cancer Res 2001;61(6):2500-4
-
(2001)
Cancer Res
, vol.61
, Issue.6
, pp. 2500-2504
-
-
Dosaka-Akita, H.1
Hommura, F.2
Mishina, T.3
-
13
-
-
68049120610
-
Expression and prognostic significance of cyclin B1 and cyclin A in non-small cell lung cancer
-
Cooper WA, Kohonen-Corish MR, McCaughan B, et al. Expression and prognostic significance of cyclin B1 and cyclin A in non-small cell lung cancer. Histopathology 2009;55(1):28-36
-
(2009)
Histopathology
, vol.55
, Issue.1
, pp. 28-36
-
-
Cooper, W.A.1
Kohonen-Corish, M.R.2
McCaughan, B.3
-
14
-
-
0031686141
-
Active cyclin A-CDK2 complex, a possible critical factor for cell proliferation in human primary lung carcinomas
-
Dobashi Y, Shoji M, Jiang SX, et al. Active cyclin A-CDK2 complex, a possible critical factor for cell proliferation in human primary lung carcinomas. Am J Pathol 1998;153(3):963-72
-
(1998)
Am J Pathol
, vol.153
, Issue.3
, pp. 963-972
-
-
Dobashi, Y.1
Shoji, M.2
Jiang, S.X.3
-
15
-
-
1342267616
-
The clinical significance of Cyclin B1 and Wee1 expression in non-small-cell lung cancer
-
Yoshida T, Tanaka S, Mogi A, et al. The clinical significance of Cyclin B1 and Wee1 expression in non-small-cell lung cancer. Ann Oncol 2004;15(2):252-6
-
(2004)
Ann Oncol
, vol.15
, Issue.2
, pp. 252-256
-
-
Yoshida, T.1
Tanaka, S.2
Mogi, A.3
-
16
-
-
0033870724
-
Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication
-
Soria JC, Jang SJ, Khuri FR, et al. Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication. Cancer Res 2000;60(15):4000-4
-
(2000)
Cancer Res
, vol.60
, Issue.15
, pp. 4000-4004
-
-
Soria, J.C.1
Jang, S.J.2
Khuri, F.R.3
-
17
-
-
33745058648
-
Expression of serine threonine kinase 15 is associated with poor differentiation in lung squamous cell carcinoma and adenocarcinoma
-
Xu HT, Ma L, Qi FJ, et al. Expression of serine threonine kinase 15 is associated with poor differentiation in lung squamous cell carcinoma and adenocarcinoma. Pathol Int 2006;56(7):375-80
-
(2006)
Pathol Int
, vol.56
, Issue.7
, pp. 375-380
-
-
Xu, H.T.1
Ma, L.2
Qi, F.J.3
-
18
-
-
84894666732
-
Aurora kinase inhibition as an anticancer strategy
-
Hilton JF, Shapiro GI. Aurora kinase inhibition as an anticancer strategy. J Clin Oncol 2014;32(1):57-9
-
(2014)
J Clin Oncol
, vol.32
, Issue.1
, pp. 57-59
-
-
Hilton, J.F.1
Shapiro, G.I.2
-
19
-
-
0242442559
-
Inactivating mutations targeting the chfr mitotic checkpoint gene in human lung cancer
-
Mariatos G, Bothos J, Zacharatos P, et al. Inactivating mutations targeting the chfr mitotic checkpoint gene in human lung cancer. Cancer Res 2003;63(21):7185-9
-
(2003)
Cancer Res
, vol.63
, Issue.21
, pp. 7185-7189
-
-
Mariatos, G.1
Bothos, J.2
Zacharatos, P.3
-
20
-
-
0033800018
-
Somatic mutation of the hBUB1 mitotic checkpoint gene in primary lung cancer
-
Gemma A, Seike M, Seike Y, et al. Somatic mutation of the hBUB1 mitotic checkpoint gene in primary lung cancer. Genes Chromosomes Cancer 2000;29(3):213-18
-
(2000)
Genes Chromosomes Cancer
, vol.29
, Issue.3
, pp. 213-218
-
-
Gemma, A.1
Seike, M.2
Seike, Y.3
-
21
-
-
0033604452
-
Search for in vivo somatic mutations in the mitotic checkpoint gene, hMAD1, in human lung cancers
-
Nomoto S, Haruki N, Takahashi T, et al. Search for in vivo somatic mutations in the mitotic checkpoint gene, hMAD1, in human lung cancers. Oncogene 1999;18(50):7180-3
-
(1999)
Oncogene
, vol.18
, Issue.50
, pp. 7180-7183
-
-
Nomoto, S.1
Haruki, N.2
Takahashi, T.3
-
22
-
-
13244295487
-
Hypermethylation of RASSF1A and BLU tumor suppressor genes in non-small cell lung cancer: Implications for tobacco smoking during adolescence
-
Marsit CJ, Kim DH, Liu M, et al. Hypermethylation of RASSF1A and BLU tumor suppressor genes in non-small cell lung cancer: implications for tobacco smoking during adolescence. Int J Cancer 2005;114(2):219-23
-
(2005)
Int J Cancer
, vol.114
, Issue.2
, pp. 219-223
-
-
Marsit, C.J.1
Kim, D.H.2
Liu, M.3
-
23
-
-
2942585478
-
CHK2 kinase expression is down-regulated due to promoter methylation in non-small cell lung cancer
-
Zhang P, Wang J, Gao W, et al. CHK2 kinase expression is down-regulated due to promoter methylation in non-small cell lung cancer. Mol Cancer 2004;3:14
-
(2004)
Mol Cancer
, vol.3
, pp. 14
-
-
Zhang, P.1
Wang, J.2
Gao, W.3
-
24
-
-
0032706396
-
Novel anti-cancer agents in development: Exciting prospects and new challenges
-
Seymour L. Novel anti-cancer agents in development: exciting prospects and new challenges. Cancer Treat Rev 1999;25(5):301-12
-
(1999)
Cancer Treat Rev
, vol.25
, Issue.5
, pp. 301-312
-
-
Seymour, L.1
-
25
-
-
0033063777
-
Cyclin-dependent kinases: Initial approaches to exploit a novel therapeutic target
-
Sausville EA, Zaharevitz D, Gussio R, et al. Cyclin-dependent kinases: initial approaches to exploit a novel therapeutic target. Pharmacol Ther 1999;82(2-3):285-92
-
(1999)
Pharmacol Ther
, vol.82
, Issue.2-3
, pp. 285-292
-
-
Sausville, E.A.1
Zaharevitz, D.2
Gussio, R.3
-
26
-
-
0036817437
-
Cyclin-dependent kinases as new targets for the prevention and treatment of cancer
-
Senderowicz AM. Cyclin-dependent kinases as new targets for the prevention and treatment of cancer. Hematol Oncol Clin North Am. 2002;16(5):1229-53
-
(2002)
Hematol Oncol Clin North Am.
, vol.16
, Issue.5
, pp. 1229-1253
-
-
Senderowicz, A.M.1
-
27
-
-
0032533599
-
Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53
-
Byrd JC, Shinn C, Waselenko JK, et al. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. Blood 1998;92(10):3804-16
-
(1998)
Blood
, vol.92
, Issue.10
, pp. 3804-3816
-
-
Byrd, J.C.1
Shinn, C.2
Waselenko, J.K.3
-
28
-
-
0034661538
-
Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia
-
Kitada S, Zapata JM, Andreeff M, et al. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood 2000;96(2):393-7
-
(2000)
Blood
, vol.96
, Issue.2
, pp. 393-397
-
-
Kitada, S.1
Zapata, J.M.2
Andreeff, M.3
-
29
-
-
0035679234
-
Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts
-
Motwani M, Jung C, Sirotnak FM, et al. Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts. Clin Cancer Res 2001;7(12):4209-19
-
(2001)
Clin Cancer Res
, vol.7
, Issue.12
, pp. 4209-4219
-
-
Motwani, M.1
Jung, C.2
Sirotnak, F.M.3
-
30
-
-
0032724295
-
Flavopiridol induces cell cycle arrest and p53-independent apoptosis in non-small cell lung cancer cell lines
-
Shapiro GI, Koestner DA, Matranga CB, et al. Flavopiridol induces cell cycle arrest and p53-independent apoptosis in non-small cell lung cancer cell lines. Clin Cancer Res 1999;5(10):2925-38
-
(1999)
Clin Cancer Res
, vol.5
, Issue.10
, pp. 2925-2938
-
-
Shapiro, G.I.1
Koestner, D.A.2
Matranga, C.B.3
-
31
-
-
0034900178
-
A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer
-
Shapiro GI, Supko JG, Patterson A, et al. A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer. Clin Cancer Res 2001;7(6):1590-9
-
(2001)
Clin Cancer Res
, vol.7
, Issue.6
, pp. 1590-1599
-
-
Shapiro, G.I.1
Supko, J.G.2
Patterson, A.3
-
32
-
-
74949088096
-
Targeting the cyclin E-Cdk-2 complex represses lung cancer growth by triggering anaphase catastrophe
-
Galimberti F, Thompson SL, Liu X, et al. Targeting the cyclin E-Cdk-2 complex represses lung cancer growth by triggering anaphase catastrophe. Clin Cancer Res 2010;16(1):109-20
-
(2010)
Clin Cancer Res
, vol.16
, Issue.1
, pp. 109-120
-
-
Galimberti, F.1
Thompson, S.L.2
Liu, X.3
-
33
-
-
48249141097
-
Synergistic inhibition of ErbB signaling by combined treatment with seliciclib and ErbB-targeting agents
-
Fleming IN, Hogben M, Frame S, et al. Synergistic inhibition of ErbB signaling by combined treatment with seliciclib and ErbB-targeting agents. Clin Cancer Res 2008;14(13):4326-35
-
(2008)
Clin Cancer Res
, vol.14
, Issue.13
, pp. 4326-4335
-
-
Fleming, I.N.1
Hogben, M.2
Frame, S.3
-
34
-
-
33846254185
-
A phase i trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days
-
Benson C, White J, De Bono J, et al. A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer 2007;96(1):29-37
-
(2007)
Br J Cancer
, vol.96
, Issue.1
, pp. 29-37
-
-
Benson, C.1
White, J.2
De Bono, J.3
-
35
-
-
77649093892
-
Phase i study of seliciclib (CYC202 or R-roscovitine) in combination with gemcitabine (gem)/cisplatin (cis) in patients with advanced non-small cell lung cancer (NSCLC)
-
Siegel-Lakhai W, Rodenstein D, Beijnen J. Phase I study of seliciclib (CYC202 or R-roscovitine) in combination with gemcitabine (gem)/cisplatin (cis) in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2005;23:2060
-
(2005)
J Clin Oncol
, vol.23
, pp. 2060
-
-
Siegel-Lakhai, W.1
Rodenstein, D.2
Beijnen, J.3
-
36
-
-
0038402755
-
Phase i clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumours. A study by the EORTC Early clinical study group (ECSG)
-
Terret C, Zanetta S, Roche H, et al. Phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumours. A study by the EORTC Early clinical study group (ECSG). Eur J Cancer 2003;39(8):1097-104
-
(2003)
Eur J Cancer
, vol.39
, Issue.8
, pp. 1097-1104
-
-
Terret, C.1
Zanetta, S.2
Roche, H.3
-
37
-
-
34250167232
-
A randomized phase II pharmacokinetic and pharmacodynamic study of indisulam as second-line therapy in patients with advanced non-small cell lung cancer
-
Talbot DC, von Pawel J, Cattell E, et al. A randomized phase II pharmacokinetic and pharmacodynamic study of indisulam as second-line therapy in patients with advanced non-small cell lung cancer. Clin Cancer Res 2007;13(6):1816-22
-
(2007)
Clin Cancer Res
, vol.13
, Issue.6
, pp. 1816-1822
-
-
Talbot, D.C.1
Von Pawel, J.2
Cattell, E.3
-
38
-
-
9444228344
-
Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts
-
Fry DW, Harvey PJ, Keller PR, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 2004;3(11):1427-38
-
(2004)
Mol Cancer Ther
, vol.3
, Issue.11
, pp. 1427-1438
-
-
Fry, D.W.1
Harvey, P.J.2
Keller, P.R.3
-
39
-
-
84885457420
-
A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies
-
Nemunaitis JJ, Small KA, Kirschmeier P, et al. A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies. J Transl Med 2013;11(1):259
-
(2013)
J Transl Med
, vol.11
, Issue.1
, pp. 259
-
-
Nemunaitis, J.J.1
Small, K.A.2
Kirschmeier, P.3
-
40
-
-
84872041276
-
AZD5438, an inhibitor of Cdk1, 2, and 9, enhances the radiosensitivity of non-small cell lung carcinoma cells
-
Raghavan P, Tumati V, Yu L, et al. AZD5438, an inhibitor of Cdk1, 2, and 9, enhances the radiosensitivity of non-small cell lung carcinoma cells. Int J Radiat Oncol Biol Phys 2012;84(4):e507-14
-
(2012)
Int J Radiat Oncol Biol Phys
, vol.84
, Issue.4
-
-
Raghavan, P.1
Tumati, V.2
Yu, L.3
-
41
-
-
77949674149
-
Efficacy of PHA-848125 a cyclin-dependent kinase inhibitor on the K-Ras(G12D)LA2 lung adenocarcinoma transgenic mouse model: Evaluation by multimodality imaging
-
Degrassi A, Russo M, Nanni C, et al. Efficacy of PHA-848125, a cyclin-dependent kinase inhibitor, on the K-Ras(G12D)LA2 lung adenocarcinoma transgenic mouse model: evaluation by multimodality imaging. Mol Cancer Ther 2010;9(3):673-81
-
(2010)
Mol Cancer Ther
, vol.9
, Issue.3
, pp. 673-681
-
-
Degrassi, A.1
Russo, M.2
Nanni, C.3
-
42
-
-
2942615282
-
Polo-like kinases and the orchestration of cell division
-
Barr FA, Sillje HH, Nigg EA. Polo-like kinases and the orchestration of cell division. Nat Rev Mol Cell Biol 2004;5(6):429-40
-
(2004)
Nat Rev Mol Cell Biol
, vol.5
, Issue.6
, pp. 429-440
-
-
Barr, F.A.1
Sillje, H.H.2
Nigg, E.A.3
-
43
-
-
0031051218
-
Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer
-
Wolf G, Elez R, Doermer A, et al. Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer. Oncogene 1997;14(5):543-9
-
(1997)
Oncogene
, vol.14
, Issue.5
, pp. 543-549
-
-
Wolf, G.1
Elez, R.2
Doermer, A.3
-
44
-
-
68049095649
-
A phase i dose escalation trial of BI2536, a novel Plk1 inhibitor, with standard dose pemetrexed in previously treated advanced or metastatic non-small cell lung cancer (NSCLC)
-
Ellis PM, Chu QS, Leighl NB. A phase I dose escalation trial of BI2536, a novel Plk1 inhibitor, with standard dose pemetrexed in previously treated advanced or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol (Meeting Abstracts) 2008;26:8115
-
(2008)
J Clin Oncol (Meeting Abstracts)
, vol.26
, pp. 8115
-
-
Ellis, P.M.1
Chu, Q.S.2
Leighl, N.B.3
-
45
-
-
77954423900
-
The efficacy and safety of BI 2536, a novel Plk-1 inhibitor, in patients with stage IIIB/IV non-small cell lung cancer who had relapsed after, or failed, chemotherapy: Results from an open-label, randomized phase II clinical trial
-
Sebastian M, Reck M, Waller CF, et al. The efficacy and safety of BI 2536, a novel Plk-1 inhibitor, in patients with stage IIIB/IV non-small cell lung cancer who had relapsed after, or failed, chemotherapy: results from an open-label, randomized phase II clinical trial. J Thorac Oncol 2010;5(7):1060-7
-
(2010)
J Thorac Oncol
, vol.5
, Issue.7
, pp. 1060-1067
-
-
Sebastian, M.1
Reck, M.2
Waller, C.F.3
-
46
-
-
84857120350
-
Final analysis of a phase i single dose-escalation study of the novel polo-like kinase 1 inhibitor BI 6727 in patients with advanced solid tumors
-
Gil T, Schoffski P, Awada A. Final analysis of a phase I single dose-escalation study of the novel polo-like kinase 1 inhibitor BI 6727 in patients with advanced solid tumors. J Clin Oncol (suppl) 2010;28:3061
-
(2010)
J Clin Oncol (Suppl)
, vol.28
, pp. 3061
-
-
Gil, T.1
Schoffski, P.2
Awada, A.3
-
47
-
-
84874606380
-
Phase i trial of the polo-like kinase (Plk) inhibitor volasertib (BI 6727) combined with cisplatin or carboplatin in patients with advanced solid tumors
-
Dumez H, Gombos A, Schöffski P. Phase I trial of the polo-like kinase (Plk) inhibitor volasertib (BI 6727) combined with cisplatin or carboplatin in patients with advanced solid tumors. J Clin Oncol 2012; 30(Suppl):abstract 3018
-
(2012)
J Clin Oncol
, vol.30
, Issue.SUPPL.
, pp. 3018
-
-
Dumez, H.1
Gombos, A.2
Schöffski, P.3
-
48
-
-
57049114832
-
The genetics of the p53 pathway, apoptosis and cancer therapy
-
Vazquez A, Bond EE, Levine AJ, et al. The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Discov 2008;7(12):979-87
-
(2008)
Nat Rev Drug Discov
, vol.7
, Issue.12
, pp. 979-987
-
-
Vazquez, A.1
Bond, E.E.2
Levine, A.J.3
-
49
-
-
0035751937
-
Assessing TP53 status in human tumours to evaluate clinical outcome
-
Soussi T, Beroud C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer 2001;1(3):233-40
-
(2001)
Nat Rev Cancer
, vol.1
, Issue.3
, pp. 233-240
-
-
Soussi, T.1
Beroud, C.2
-
50
-
-
85047687410
-
The mutant p53-conformation modifying drug, CP-31398, can induce apoptosis of human cancer cells and can stabilize wild-type p53 protein
-
Takimoto R, Wang W, Dicker DT, et al. The mutant p53-conformation modifying drug, CP-31398, can induce apoptosis of human cancer cells and can stabilize wild-type p53 protein. Cancer Biol Ther 2002;1(1):47-55
-
(2002)
Cancer Biol Ther
, vol.1
, Issue.1
, pp. 47-55
-
-
Takimoto, R.1
Wang, W.2
Dicker, D.T.3
-
51
-
-
24044466754
-
Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs
-
Bykov VJ, Issaeva N, Zache N, et al. Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs. J Biol Chem 2005;280(34):30384-91
-
(2005)
J Biol Chem
, vol.280
, Issue.34
, pp. 30384-30391
-
-
Bykov, V.J.1
Issaeva, N.2
Zache, N.3
-
52
-
-
33744974524
-
P53 and its downstream proteins as molecular targets of cancer
-
Sun Y. p53 and its downstream proteins as molecular targets of cancer. Mol Carcinog 2006;45(6):409-15
-
(2006)
Mol Carcinog
, vol.45
, Issue.6
, pp. 409-415
-
-
Sun, Y.1
-
53
-
-
10744221485
-
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2
-
Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004;303(5659):844-8
-
(2004)
Science
, vol.303
, Issue.5659
, pp. 844-848
-
-
Vassilev, L.T.1
Vu, B.T.2
Graves, B.3
-
54
-
-
0037370357
-
Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding
-
Wang W, Takimoto R, Rastinejad F, et al. Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding. Mol Cell Biol 2003;23(6):2171-81
-
(2003)
Mol Cell Biol
, vol.23
, Issue.6
, pp. 2171-2181
-
-
Wang, W.1
Takimoto, R.2
Rastinejad, F.3
-
55
-
-
0036128899
-
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
-
Bykov VJ, Issaeva N, Shilov A, et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 2002;8(3):282-8
-
(2002)
Nat Med
, vol.8
, Issue.3
, pp. 282-288
-
-
Bykov, V.J.1
Issaeva, N.2
Shilov, A.3
-
56
-
-
49049096115
-
PRIMA-1 synergizes with adriamycin to induce cell death in non-small cell lung cancer cells
-
Magrini R, Russo D, Ottaggio L, et al. PRIMA-1 synergizes with adriamycin to induce cell death in non-small cell lung cancer cells. J Cell Biochem 2008;104(6):2363-73
-
(2008)
J Cell Biochem
, vol.104
, Issue.6
, pp. 2363-2373
-
-
Magrini, R.1
Russo, D.2
Ottaggio, L.3
-
57
-
-
84884371945
-
Chemopreventive effects of the p53-modulating agents CP-31398 and Prima-1 in tobacco carcinogen-induced lung tumorigenesis in A/J mice
-
Rao CV, Patlolla JM, Qian L, et al. Chemopreventive effects of the p53-modulating agents CP-31398 and Prima-1 in tobacco carcinogen-induced lung tumorigenesis in A/J mice. Neoplasia 2013;15(9): 1018-27
-
(2013)
Neoplasia
, vol.15
, Issue.9
, pp. 1018-1027
-
-
Rao, C.V.1
Patlolla, J.M.2
Qian, L.3
-
58
-
-
0033526357
-
Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer
-
Swisher SG, Roth JA, Nemunaitis J, et al. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst 1999;91(9):763-71
-
(1999)
J Natl Cancer Inst
, vol.91
, Issue.9
, pp. 763-771
-
-
Swisher, S.G.1
Roth, J.A.2
Nemunaitis, J.3
-
59
-
-
77952135152
-
INGN-225: A dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: Observed association between immune response and enhanced chemotherapy effect
-
Chiappori AA, Soliman H, Janssen WE, et al. INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect. Expert Opin Biol Ther 2010;10(6):983-91
-
(2010)
Expert Opin Biol Ther
, vol.10
, Issue.6
, pp. 983-991
-
-
Chiappori, A.A.1
Soliman, H.2
Janssen, W.E.3
-
60
-
-
74549189337
-
New insights into checkpoint kinase 1 in the DNA damage response signaling network
-
Dai Y, Grant S. New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clin Cancer Res 2010;16(2):376-83
-
(2010)
Clin Cancer Res
, vol.16
, Issue.2
, pp. 376-383
-
-
Dai, Y.1
Grant, S.2
-
61
-
-
84873100369
-
Phase i dose-escalation study to examine the safety and tolerability of LY2603618 a checkpoint 1 kinase inhibitor administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer
-
Weiss GJ, Donehower RC, Iyengar T, et al. Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer. Invest New Drugs 2013;31(1):136-44
-
(2013)
Invest New Drugs
, vol.31
, Issue.1
, pp. 136-144
-
-
Weiss, G.J.1
Donehower, R.C.2
Iyengar, T.3
-
62
-
-
77950650401
-
In vitro and in vivo radiation sensitization of human tumor cells by a novel checkpoint kinase inhibitor, AZD7762
-
Mitchell JB, Choudhuri R, Fabre K, et al. In vitro and in vivo radiation sensitization of human tumor cells by a novel checkpoint kinase inhibitor, AZD7762. Clin Cancer Res 2010;16(7):2076-84
-
(2010)
Clin Cancer Res
, vol.16
, Issue.7
, pp. 2076-2084
-
-
Mitchell, J.B.1
Choudhuri, R.2
Fabre, K.3
-
63
-
-
84872494989
-
Phase i open-label, dose-escalation study of AZD7762 in combination with irinotecan (irino) in patients with advanced solid tumors
-
Ho A, Bendell J, Cleary J. Phase I, open-label, dose-escalation study of AZD7762 in combination with irinotecan (irino) in patients with advanced solid tumors. J Clin Oncol 2011;29(Suppl 15):3033
-
(2011)
J Clin Oncol
, vol.29
, Issue.SUPPL. 15
, pp. 3033
-
-
Ho, A.1
Bendell, J.2
Cleary, J.3
-
64
-
-
79960253104
-
Phase i dose-escalation study ofAZD7762 in combination with gemcitabine (gem) in patients with advanced solid tumors
-
Sausville E, Barker P, Agbo F. Phase I dose-escalation study ofAZD7762 in combination with gemcitabine (gem) in patients with advanced solid tumors. J Clin Oncol 2011;29(Suppl 15):3058
-
(2011)
J Clin Oncol
, vol.29
, Issue.SUPPL. 15
, pp. 3058
-
-
Sausville, E.1
Barker, P.2
Agbo, F.3
-
65
-
-
79651475663
-
A phase i dose-escalation study of SCH 900776, a selective inhibitor of checkpoint kinase 1(CHK1), in combination with gemcitabine (Gem) in subjects with advanced solid tumors
-
Daud A, Springett G, Mendelson D. A phase I dose-escalation study of SCH 900776, a selective inhibitor of checkpoint kinase 1(CHK1), in combination with gemcitabine (Gem) in subjects with advanced solid tumors. J Clin Oncol 2010;28(Suppl 15):3064
-
(2010)
J Clin Oncol
, vol.28
, Issue.SUPPL. 15
, pp. 3064
-
-
Daud, A.1
Springett, G.2
Mendelson, D.3
-
66
-
-
79958804691
-
Phase i clinical trial of gemcitabine (GEM) in combination with PF-00477736 (PF-736), a selective inhibitor of CHK1 kinase
-
Brega N, McArthur G, Britten C. Phase I clinical trial of gemcitabine (GEM) in combination with PF-00477736 (PF-736), a selective inhibitor of CHK1 kinase. J Clin Oncol 2010;28(Suppl 15):3062
-
(2010)
J Clin Oncol
, vol.28
, Issue.SUPPL. 15
, pp. 3062
-
-
Brega, N.1
McArthur, G.2
Britten, C.3
-
67
-
-
78449302142
-
Targeted radiosensitization of cells expressing truncated DNA polymerase {beta}
-
Neijenhuis S, Verwijs-Janssen M, van den Broek LJ, et al. Targeted radiosensitization of cells expressing truncated DNA polymerase {beta}. Cancer Res 2010;70(21):8706-14
-
(2010)
Cancer Res
, vol.70
, Issue.21
, pp. 8706-8714
-
-
Neijenhuis, S.1
Verwijs-Janssen, M.2
Van Den Broek, L.J.3
-
68
-
-
0037335861
-
Essential and dispensable roles of ATR in cell cycle arrest and genome maintenance
-
Brown EJ, Baltimore D. Essential and dispensable roles of ATR in cell cycle arrest and genome maintenance. Genes Dev 2003;17(5):615-28
-
(2003)
Genes Dev
, vol.17
, Issue.5
, pp. 615-628
-
-
Brown, E.J.1
Baltimore, D.2
-
69
-
-
84899440993
-
Discovery of AZD6738, a potent and selective inhibitor with the potential to test the clinical efficacy of ATR kinase inhibition in cancer patients
-
Jones C, Blades K, Foote K. Discovery of AZD6738, a potent and selective inhibitor with the potential to test the clinical efficacy of ATR kinase inhibition in cancer patients. Cancer Res 2013;73(Suppl 8):2348
-
(2013)
Cancer Res
, vol.73
, Issue.SUPPL. 8
, pp. 2348
-
-
Jones, C.1
Blades, K.2
Foote, K.3
-
70
-
-
78649476052
-
Shared and separate functions of polo-like kinases and aurora kinases in cancer
-
Lens SM, Voest EE, Medema RH. Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat Rev Cancer 2010;10(12):825-41
-
(2010)
Nat Rev Cancer
, vol.10
, Issue.12
, pp. 825-841
-
-
Lens, S.M.1
Voest, E.E.2
Medema, R.H.3
-
71
-
-
84874632972
-
Emerging mitotic inhibitors for non-small cell carcinoma
-
Casaluce F, Sgambato A, Maione P, et al. Emerging mitotic inhibitors for non-small cell carcinoma. Expert Opin Emerg Drugs 2013;18(1):97-107
-
(2013)
Expert Opin Emerg Drugs
, vol.18
, Issue.1
, pp. 97-107
-
-
Casaluce, F.1
Sgambato, A.2
Maione, P.3
-
72
-
-
84874626828
-
Phase I/II study of the investigational aurora A kinase (AAK) inhibitor MLN8237 (alisertib) in patients (pts) with non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), breast cancer (BrC), head/neck cancer (H&N), and gastroesophageal (GE) adenocarcinoma: Preliminary phase II results
-
Lee P, Alvarez R, Melichar B. Phase I/II study of the investigational aurora A kinase (AAK) inhibitor MLN8237 (alisertib) in patients (pts) with non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), breast cancer (BrC), head/neck cancer (H&N), and gastroesophageal (GE) adenocarcinoma: preliminary phase II results. J Clin Oncol (ASCO Annual Meeting Proceedings) 2012;30(Suppl):3010
-
(2012)
J Clin Oncol (ASCO Annual Meeting Proceedings)
, vol.30
, Issue.SUPPL.
, pp. 3010
-
-
Lee, P.1
Alvarez, R.2
Melichar, B.3
-
73
-
-
84892916318
-
Phase II Study of alisertib, a selective aurora a kinase inhibitor, in relapsed and refractory aggressive B-and T-cell non-hodgkin lymphomas
-
Friedberg JW, Mahadevan D, Cebula E, et al. Phase II Study of alisertib, a selective aurora a kinase inhibitor, in relapsed and refractory aggressive B-and T-cell non-hodgkin lymphomas. J Clin Oncol 2014;32(1):44-50
-
(2014)
J Clin Oncol
, vol.32
, Issue.1
, pp. 44-50
-
-
Friedberg, J.W.1
Mahadevan, D.2
Cebula, E.3
-
74
-
-
84861497210
-
Inhibitors of cell cycle kinases: Recent advances and future prospects as cancer therapeutics
-
Stone A, Sutherland RL, Musgrove EA. Inhibitors of cell cycle kinases: recent advances and future prospects as cancer therapeutics. Crit Rev Oncog 2012;17(2):175-98
-
(2012)
Crit Rev Oncog
, vol.17
, Issue.2
, pp. 175-198
-
-
Stone, A.1
Sutherland, R.L.2
Musgrove, E.A.3
-
75
-
-
45849087334
-
Phase i study of flavopiridol in combination with Paclitaxel and Carboplatin in patients with non-small-cell lung cancer
-
George S, Kasimis BS, Cogswell J, et al. Phase I study of flavopiridol in combination with Paclitaxel and Carboplatin in patients with non-small-cell lung cancer. Clin Lung Cancer 2008;9(3):160-5
-
(2008)
Clin Lung Cancer
, vol.9
, Issue.3
, pp. 160-165
-
-
George, S.1
Kasimis, B.S.2
Cogswell, J.3
-
76
-
-
84899442417
-
A randomized phase 2 study of the cyclin-dependent kinase (CDK) inhibitor Dinaciclib (SCH 727965) in patients with non-small cell lung cancer (NSCLC)
-
Warren SL, Nemunaitis J, Stephenson J. A randomized phase 2 study of the cyclin-dependent kinase (CDK) inhibitor Dinaciclib (SCH 727965) in patients with non-small cell lung cancer (NSCLC). Cancer Res (Supplement) 2011;71:2242
-
(2011)
Cancer Res (Supplement)
, vol.71
, pp. 2242
-
-
Warren, S.L.1
Nemunaitis, J.2
Stephenson, J.3
-
77
-
-
84875505550
-
Phase i study of the safety tolerability and pharmacokinetics of PHA-848125AC a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor in patients with advanced solid malignancies
-
Weiss GJ, Hidalgo M, Borad MJ, et al. Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies. Invest New Drugs 2012;30(6):2334-43
-
(2012)
Invest New Drugs
, vol.30
, Issue.6
, pp. 2334-2343
-
-
Weiss, G.J.1
Hidalgo, M.2
Borad, M.J.3
-
78
-
-
84870567659
-
A phase i open-label dose-escalation study of intravenous BI 2536 together with pemetrexed in previously treated patients with non-small-cell lung cancer
-
Ellis PM, Chu QS, Leighl N, et al. A phase I open-label dose-escalation study of intravenous BI 2536 together with pemetrexed in previously treated patients with non-small-cell lung cancer. Clin Lung Cancer 2013;14(1):19-27
-
(2013)
Clin Lung Cancer
, vol.14
, Issue.1
, pp. 19-27
-
-
Ellis, P.M.1
Chu, Q.S.2
Leighl, N.3
-
79
-
-
84883487392
-
Phase i dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours
-
Seto T, Esaki T, Hirai F, et al. Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours. Cancer Chemother Pharmacol 2013;72(3):619-27
-
(2013)
Cancer Chemother Pharmacol
, vol.72
, Issue.3
, pp. 619-627
-
-
Seto, T.1
Esaki, T.2
Hirai, F.3
-
80
-
-
84882716595
-
Phase i dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumors
-
Seto T, Esaki T, Hirai F, et al. Phase I dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumors. J Clin Oncol 2012;30(Suppl):abstract 3045
-
(2012)
J Clin Oncol
, vol.30
, Issue.SUPPL.
, pp. 3045
-
-
Seto, T.1
Esaki, T.2
Hirai, F.3
-
81
-
-
79960253104
-
Phase i dose-escalation study of AZD7762 in combination with gemcitabine (gem) in patients (pts) with advanced solid tumors
-
Sausville EA, LoRusso P, Carducci MA, et al. Phase I dose-escalation study of AZD7762 in combination with gemcitabine (gem) in patients (pts) with advanced solid tumors. J Clin Oncol 2011;29(Suppl):abstract 3058
-
(2011)
J Clin Oncol
, vol.29
, Issue.SUPPL.
, pp. 3058
-
-
Sausville, E.A.1
Lorusso, P.2
Carducci, M.A.3
-
82
-
-
84872494989
-
Phase I, open-label, dose-escalation study of AZD7762 in combination with irinotecan (irino) in patients (pts) with advanced solid turmors
-
Ho A, Bendell J, Cleary J, et al. Phase I, open-label, dose-escalation study of AZD7762 in combination with irinotecan (irino) in patients (pts) with advanced solid turmors. J Clin Oncol 2011;29(Suppl):3033
-
(2011)
J Clin Oncol
, vol.29
, Issue.SUPPL.
, pp. 3033
-
-
Ho, A.1
Bendell, J.2
Cleary, J.3
-
83
-
-
79958804691
-
Phase i clinical trial of gemcitabine (GEM) in combination with PF-00477736 (PF-736), a selective inhibitor of CHK1 kinase
-
Brega N, McArthur G, Britten C, et al. Phase I clinical trial of gemcitabine (GEM) in combination with PF-00477736 (PF-736), a selective inhibitor of CHK1 kinase. J Clin Oncol 2010;28(Suppl):3062
-
(2010)
J Clin Oncol
, vol.28
, Issue.SUPPL.
, pp. 3062
-
-
Brega, N.1
McArthur, G.2
Britten, C.3
-
84
-
-
79651475663
-
A phase i dose-escalation study of SCH 900776, a selective inhibitor of checkpoint kinase 1 (CHK1), in combination with gemcitabine (Gem) in subjects with advanced solid tumors
-
Daud A, Springett GM, Mendelson DS, et al. A phase I dose-escalation study of SCH 900776, a selective inhibitor of checkpoint kinase 1 (CHK1), in combination with gemcitabine (Gem) in subjects with advanced solid tumors. J Clin Oncol 2010;28(Suppl):abstract 3064
-
(2010)
J Clin Oncol
, vol.28
, Issue.SUPPL.
, pp. 3064
-
-
Daud, A.1
Springett, G.M.2
Mendelson, D.S.3
-
85
-
-
79952223661
-
A phase i dose-escalation study of BI 811283, an Aurora B inhibitor, administered every three weeks in patients with advanced solid tumors
-
Mross KB, Scheulen ME, Frost A, et al. A phase I dose-escalation study of BI 811283, an Aurora B inhibitor, administered every three weeks in patients with advanced solid tumors. J Clin Oncol 2010;28(Suppl):3011
-
(2010)
J Clin Oncol
, vol.28
, Issue.SUPPL.
, pp. 3011
-
-
Mross, K.B.1
Scheulen, M.E.2
Frost, A.3
-
86
-
-
84899410368
-
Phase II study of danusertib (D) in advanced/metastatic non-small cell lung cancers (NSCLC)
-
Gauler TC, Besse B, Novello S, et al. Phase II study of danusertib (D) in advanced/metastatic non-small cell lung cancers (NSCLC). J Clin Oncol 2013;31(Suppl):e19138
-
(2013)
J Clin Oncol
, vol.31
, Issue.SUPPL.
-
-
Gauler, T.C.1
Besse, B.2
Novello, S.3
|